Does mycophenolate mofetil improve lung function in connective tissue disease-associated interstitial lung disease?
In a large diverse cohort of CTD-ILD, MMF was well tolerated and had a low rate of discontinuation. Treatment with MMF was associated with either stable or improved pulmonary physiology over a median 2.5 years of followup. MMF appears to be a promising therapy for the spectrum of CTD-ILD.
FXN promoter silencing in FRDA is dependent on the length of the expanded GAA-TR mutation.